Ticker	Current Price	Change	Graph
IBB	102.57	0.7 (0.68%)
XBI	85.73	0.72 (0.83%)

Deals, M&A

UPDATED: Can Takeda actually close its $65B deal to buy Shire? Maybe, but analysts aren't sure they should

Drug Development, Setbacks

Daiichi Sankyo concedes an early setback on Duchenne MD drug, but doubles down on development

People, Special

The under-40s: How does the next generation of biopharma executives view the future?

Latest

NEWAfter mega-round investment, ADC Therapeutics cans PhI trial in HER2 →

After decades in the big leagues, Martin Mackay is going small — and he's delighted →

Celldex brings out the ax in wake of breast cancer drug disaster, chopping a quarter of its staff →

'Site-less' trials in mind, Novartis launches an app for ophthalmology research →

Done deal? Takeda reaches a ‘breakthrough’ in Shire merger talks as deal announcement looms — Reuters →

Arrested and charged with fraud, PixarBio CEO Frank Reynolds could face up to 20 years in prison →

UPDATED: SCOTUS to biopharma: Inter partes reviews are here to stay, deal with it →

Biotech stars Schleifer and Yancopoulos share $52M in 2017 compensation, even though Regeneron's share price swooned →

UPDATED: Shire says Takeda has come up with a new buyout offer as reports spotlight a looming handshake deal →

Top News

AstraZeneca’s Imfinzi/tremelimumab combo fizzles again on lung cancer

John Carroll

Longtime Sanofi R&D chief Elias Zerhouni is on his way out, handing the research reins to Roche vet John Reed

John Carroll

EMA committee recommends Alnylam's early-stage ATTR amyloidosis drug for orphan status

Amber Tong

Pfizer hits stumbling block on Herceptin rival, but wins 'breakthrough' status on MenB vaccine

Brittany Meiling

Prothena’s lead drug NEOD001 just imploded in 2 late-stage studies — and there’s nothing left to salvage

John Carroll

More news

Protocols

Quick hits from around the biopharma web

Apr 24

Sofinnova leads $32.4 million round for Italy's EryDel; Celgene expands collaboration with Zymeworks

Apr 23

Sanofi loses its German CSO and diabetes chief to Grünenthal; Roche touts longterm advantages of Ocrevus in treating multiple sclerosis

Apr 19

Tocagen licenses immunotherapy to ApolloBio for $16M upfront; WuXi AppTec unveils expanded lab testing site in New Jersey

Apr 18

Sanofi CFO Jerome Contamine hits the exit; Struggling Fibrocell triggers a strategic review

More Protocols

Premium

The 2-trial hurdle for drug approvals is steadily losing ground. Are we devaluing the industry's R&D gold standard?

Where does the science come from? The top 20 NIH-funded institutions in 2017

The good, the bad and the ugly for the top 15 spenders in the global drug R&D business: 2018

Bristol-Myers offers some eagerly awaited Checkmate-227 results, but they're not changing medical practice -- yet

What are the top 10 corporate VCs in biopharma today? And what do they want to fund — or steer clear of?

Where the money is: Top 100 VCs investing in US biotechs during 2017

Marco

Hot BioTwitter bot - last updated ago

Most Viral

BREAKING: Takeda reaches preliminary deal to buy Shire for close to $65B

ENDPOINTS NEWS John Carroll a day

Exclusive: Shire, Takeda reach breakthrough in deal talks - sources

Reuters a day

Study of ADCT-502 in Patients With Advanced Solid Tumors With HER2 Expression - Full Text View - ClinicalTrials.gov

ClinicalTrials a day

Supreme Court rules that patent reviews detested by pharma are constitutional - STAT

STAT a day

Amgen still has no magic pill to solve its zero-growth problem - STAT

STAT a day

PureTech Health Appoints Joep Muijrers as Chief Financial Officer

BusinessWire a day

Biogen's rain-making rare-disease drug hits a sales slump - STAT

STAT a day

Prothena’s Pronto failure raises pipeline doubts

Evaluate Pharma a day

In a blow for pharma, Supreme Court upholds the hated IPR patent challenge

FiercePharma a day

Daiichi DMD trial misses primary efficacy endpoint

FierceBiotech a day

Latest

Pink Sheet

FDA Pulmonary/Rheumatology Division Sees Management Shakeup

Nature

A lab co-op helps young faculty members to thrive

Evaluate Pharma

Prothena’s Pronto failure raises pipeline doubts

BioCentury

BioCentury - Prothena plummets after amyloidosis failure

GSK

Quarterly results | GSK

BioWorld

Shire digs Takeda's remix: revised offer worth $64B

Reuters

Europe's Most Innovative Universities - 2018

STAT

Amgen still has no magic pill to solve its zero-growth problem - STAT

Financial Times

Takeda/Shire: kill or cure

Reuters

Shire bid marks Takeda's latest - and biggest - push for global status

Hot This Week

1

National Geographic News

First-of-Its-Kind Footage Shows Cells Moving in Live Animals

2

ENDPOINTS NEWS

BREAKING: Takeda reaches preliminary deal to buy Shire for close to $65B

3

Reuters

Exclusive: Shire, Takeda reach breakthrough in deal talks - sources

4

The New Yorker

A Stunning Cure for One of the World's Most Devastating Blood Diseases

5

ClinicalTrials

Study of ADCT-502 in Patients With Advanced Solid Tumors With HER2 Expression - Full Text View - ClinicalTrials.gov

6

STAT

Supreme Court rules that patent reviews detested by pharma are constitutional - STAT

7

WSJ

In the War on Cancer, Truth Becomes a Casualty

8

Reuters

Exclusive: Allergan in talks to acquire Shire, competing against...

9

OUP Academic

Selective RET Kinase Inhibition for Patients with RET- Altered Cancers | Annals of Oncology | Oxford Academic

10

WSJ

UPDATED: Can Takeda actually close its $65B deal to buy Shire? Maybe, but analysts aren't sure they should

Daiichi Sankyo concedes an early setback on Duchenne MD drug, but doubles down on development

The under-40s: How does the next generation of biopharma executives view the future?

Latest

NEWAfter mega-round investment, ADC Therapeutics cans PhI trial in HER2 →

After decades in the big leagues, Martin Mackay is going small — and he's delighted →

Celldex brings out the ax in wake of breast cancer drug disaster, chopping a quarter of its staff →

'Site-less' trials in mind, Novartis launches an app for ophthalmology research →

Done deal? Takeda reaches a ‘breakthrough’ in Shire merger talks as deal announcement looms — Reuters →

Arrested and charged with fraud, PixarBio CEO Frank Reynolds could face up to 20 years in prison →

UPDATED: SCOTUS to biopharma: Inter partes reviews are here to stay, deal with it →

Biotech stars Schleifer and Yancopoulos share $52M in 2017 compensation, even though Regeneron's share price swooned →

UPDATED: Shire says Takeda has come up with a new buyout offer as reports spotlight a looming handshake deal →

Top News

Protocols

Premium

The 2-trial hurdle for drug approvals is steadily losing ground. Are we devaluing the industry's R&D gold standard?

Where does the science come from? The top 20 NIH-funded institutions in 2017

The good, the bad and the ugly for the top 15 spenders in the global drug R&D business: 2018

Bristol-Myers offers some eagerly awaited Checkmate-227 results, but they're not changing medical practice -- yet

What are the top 10 corporate VCs in biopharma today? And what do they want to fund — or steer clear of?

Where the money is: Top 100 VCs investing in US biotechs during 2017

Most Viral

Latest

Hot This Week

Contact Endpoints News

Sign in to Endpoints News

Request a magic link

Set a new password